
The authors relay the outcome of a two-day workshop that brought together regulators and generic-drug industry representatives.
Gary Buehler is director of the Office of Generic Drugs at the US Food and Drug Administration.

The authors relay the outcome of a two-day workshop that brought together regulators and generic-drug industry representatives.

Published: October 2nd 2009 | Updated: